Emerging roles of ALK in immunity and insights for immunotherapy
- Lan Wang,
- Vivian Wai Yan Lui(corresponding author)
- Chinese University of Hong Kong
Scholary Output:
Contribution to journal
Review article
Peer-review
Open access
Sustainable Development Goals
SDG 3 Good Health and Well
Abstract
Anaplastic lymphoma kinase (ALK) is mostly known for its oncogenic role in several human cancers. Recent evidences clearly indicate new roles of ALK and its genetic aberrations (e.g. gene rearrangements and mutations) in immune evasion, innate and cell-mediated immunity. New ALK-related immunotherapy approaches are demonstrating both preclinical and clinical promises. Here, we provide a timely review on the most updated laboratory and patient-related findings on ALK and immunity, which would grant us important insights for the development of novel ALK immunotherapies for ALK-altered cancers.
Publication Information
Output type
Scholary Output:
Contribution to journal
Review article
Peer-reviewOriginal language
English (US)Article number
426Journal (Volume, Issue Number)
Cancers (Volume 12, Issue 2)Publication milestones
- Published - 02/2020
Publication status
Published - 02/2020
ISSN
2072-6694Publication IDs
- Scopus: 85079478688
Publication metrics
Metrics
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Social media
6
Citation count
22
Captures
44
Funding Details
This is funded by the General Research Fund (#17121616 to VWYL, Research Grant Council, Hong Kong Government, Hong Kong SAR). V.W.Y.L. also receives fundings from the Research Grant Council, General Research Fund—17114814, 17121616, 14168517, and R4017-18; Research Impact Fund; the Health and Medical Research Fund (HMRF#15160691, the Health and Medical Research Fund, the Food and Health Bureau, The Government of the Hong Kong Special Administrative Region); University-Industry Collaboration Program (UIM/329; Innovation and Technology Fund, Hong Kong government, Hong Kong SAR and Lee’s Pharmaceutical (HK) Limited); the Hong Kong Cancer Fund, Hong Kong SAR; Start-up Fund from the School of Biomedical Sciences, Faculty of Medicine, CUHK. Acknowledgments: This is funded by General Research Fund #17121616, Research Grant Council, Hong Kong Government, Hong Kong SAR.
FundersFunding numbers
Research Grant Council, Hong Kong Government
-School of Biomedical Sciences
-University-Industry Collaboration Program
UIM/329
研究資助局
-CUHK
-FHB
-HMRF
15160691
ITF
-General Research Fund of Shanghai Normal University
14168517, 17114814, R4017-18
HKFC
-HK
-